Table 1.
Maternal and infant characteristics
| Methadone | Buprenorphine | |
|---|---|---|
|
| ||
| n = 129 | Mean/Percent (SD) | Mean/Percent (SD) |
| MATERNAL | ||
| Maternal weight at delivery (lbs) | 171.5 (4.6) | 165.4 (4.4) |
| Vaginal delivery | 63.0% | 70.7% |
| Maternal maintenance dose at delivery (mg) | 85.0 (4.2) | 16.6 (1.0) |
| Days of study medication | 158.7 (6.6) | 168.8 (5.7) |
| UDS two weeks prior to delivery | ||
| Benzodiazepines | 1.4% | 5.6% |
| Cocaine | 5.6% | 9.3% |
| Opiates | 5.6% | 11.1% |
| Cigarettes (N) 24 hours prior to delivery | 12.2 (0.9) | 8.7 (0.9) |
| SSRIs | 21.9% | 27.8% |
| Anxiolytics | 27.8 % | 40.4% |
| INFANT | ||
| EGA at delivery (weeks) | 37.9 (0.3) | 39.1 (0.3) |
| Birth weight (gm) | 2878.5 (66.3) | 3093.7 (72.6) |
| Peak NAS score prior to treatment | 12.8 (0.6) | 11.0 (0.7) |
| Treated for NAS | 56.9% | 47.4% |
| Length of treatment (days) | 9.9 (1.6) | 4.1 (1.0) |
| Total amount of morphine (mg) | 10.4 (2.6) | 1.1 (0.7) |
Note: UDS: urine drug screen; SSRIs: selective serotonin reuptake inhibitors; Days of study medication: maternal maintenance medication; EGA: estimated gestational age; NAS: neonatal abstinence syndrome